ArticleCancer biology & therapy2010
Reevaluating cathepsin D as a biomarker for breast cancer: serum activity levels versus histopathology.
Article in Cancer biology & therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review.British journal of cancer · 2010Pooled it
- Lung endothelial PEAR1 induces tumor cell dormancy.Molecular cancer · 2025Article
- Broadening Horizons: Exploring the Cathepsin Family as Therapeutic Targets for Alzheimer's Disease.Aging and disease · 2024Review
- Golgi defect as a major contributor to lysosomal dysfunction.Frontiers in cell and developmental biology · 2024Review
- Review
- Cathepsin D deficiency in mammary epithelium transiently stalls breast cancer by interference with mTORC1 signaling.Nature communications · 2020Article
- Classification models for Invasive Ductal Carcinoma Progression, based on gene expression data-trained supervised machine learning.Scientific reports · 2020Article
- Cathepsins: Proteases that are vital for survival but can also be fatal.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2018Review
- Expression and Localization of Cathepsins B, D and G in Cancer Stem Cells in Liver Metastasis From Colon Adenocarcinoma.Frontiers in surgery · 2018Article
- Cathepsin D inhibitors as potential therapeutics for breast cancer treatment: Molecular docking and bioevaluation against triple-negative and triple-positive breast cancers.Molecular diversity · 2016Article
- Aptamers Selected to Postoperative Lung Adenocarcinoma Detect Circulating Tumor Cells in Human Blood.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- N,N'-dinitrosopiperazine-mediated AGR2 is involved in metastasis of nasopharyngeal carcinoma.PloS one · 2014Article
- Monitoring of peri-distal gastrectomy carbohydrate antigen 19-9 level in gastric juice and its significance.International journal of clinical and experimental medicine · 2014Article
- Detection of perioperative cancer antigen 72-4 in gastric juice pre- and post-distal gastrectomy and its significances.Medical oncology (Northwood, London, England) · 2013Article
- Article
- Article
- The feasibility of enzyme targeted activation for amino acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential targeted enzyme.Molecules (Basel, Switzerland) · 2012Article
- c-Myb regulates matrix metalloproteinases 1/9, and cathepsin D: implications for matrix-dependent breast cancer cell invasion and metastasis.Molecular cancer · 2012Article
- Cathepsin D Expression in Colorectal Cancer: From Proteomic Discovery through Validation Using Western Blotting, Immunohistochemistry, and Tissue Microarrays.International journal of proteomics · 2012Article
- Clinical and Biological Significance of Cathepsin D Levels in Breast Cancer Cytosol in Women Over 70 years.Biomarkers in cancer · 2012Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 6 institutions in 3 countries.
Funding
Abstract
Cathepsin D is a lysosomal hydrolase involved in intra- and extracellular proteolysis. This enzyme is aberrantly produced and processed in malignancy, and most notably is over-secreted into the tumor cell microenvironment. This hyper-secretion may lead to excessive degradation of the extracellular matrix, and contribute to tumor progression and metastases. These phenomena have been established in vitro, and there is evidence that Cathepsin D is similarly dysregulated in human breast cancer patients. Because breast cancer lacks an effective screening or surveillance biomarker, here we address the hypothesis that serum Cathepsin D activity may be useful to assess the presence or progression of breast cancer in females. While representative histologic sections from various disease-specific cohorts confirm previous findings that increased Cathepsin D production and secretion correlate with tumor progression, we report no difference in serum Cathepsin D activity between patients who are disease free, patients with pre-invasive or limited invasive disease, and patients with metastatic disease. Furthermore, in patients with known metastatic disease, there were no clinical variables associated with significantly different serum Cathepsin D activity. However, the immunohistochemical localization of Cathepsin D expression in histopathologic sections from breast cancer patients correlates with disease progression. Based on the serum results, and in contradistinction to Cathepsin D localization in breast cancer tissues, our findings support using Cathepsin D as a reliable histopathology biomarker for disease progression, but not for serum screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.